Poster

Efficacy of Lumateperone in Pooled Short-Term Late-Phase Clinical Trials for the Treatment of Major Depressive Episodes Associated With Bipolar II Disorder

This post hoc, pooled analysis of 3 short-term, placebo-controlled studies evaluated the efficacy of once-daily lumateperone 42mg monotherapy and adjunctive therapy in patients experienci...

William Rowe , MSN, RN, ACNP, BC;

10/26/2023

Emotion Regulation Across Psychiatric Disorders: A Systematic Review and Meta-analysis

A systematic review and meta-analysis exploring the magnitude of emotion dysregulation in individuals with various diagnosed psychiatric conditions compared to healthy individuals. Using ...

Jordan Stellern , BS;

10/26/2023

EMPOWERing the Next-Generation: A phase 2 Program to Evaluate Emraclidine, a Selective M4 Positive Allosteric Modulator (PAM), for the Treatment of Schizophrenia

Detailed study designs for the EMPOWER program will be presented. Primary outcome measure for EMPOWER 1 and 2 is change from baseline in PANSS total score at week 6. Other outcome measure...

Koji Takahashi , PhD;

10/26/2023

Enhancing Access to Mental Health Services: The Growing Use of Telemedicine Among Physician Assistants/Associates in Psychiatry

Challenges to accessing affordable and high-quality mental health care persist amidst significantly rising demand. This study explored the use of telemedicine technology among PAs practic...

Mirela Bruza-Augatis , MS, PA-C;

10/26/2023

Equivalent Antidepressant Outcomes with Esketamine in TMS Non-Responders

Both Transcranial Magnetic Stimulation (TMS) and Esketamine are FDA approved therapies for patients with Major Depressive Disorder who have failed at least one conventional antidepressant...

Tobias F. Marton , MD, PhD;

10/26/2023

Esketamine Nasal Spray Improves Functioning in Patients with Treatment Resistant Depression: Results from ESCAPE‑TRD

This analysis evaluated changes in functioning and productivity in patients with treatment resistant depression who received either esketamine nasal spray or quetiapine extended release, ...

Hannah Bowrey , PhD;

10/26/2023

Efficacy of Brexpiprazole in Patients With Agitation Associated With Alzheimer’s Dementia Analyzed by Presence or Absence of Psychosis: a Pooled Analysis

This post hoc analysis explored the efficacy of brexpiprazole 2 or 3 mg/day in patients with agitation associated with Alzheimer’s dementia, based on presence or absence of psychosis at b...

Anja Farovik , PhD;

10/26/2023

Efficacy of Fremanezumab in Reducing Depression in Patients With Migraine and Major Depressive Disorder: Results of the UNITE Study

Depression is a prevalent comorbidity associated with migraine. In patients with migraine and major depressive disorder, treatment with fremanezumab was associated with significant reduct...

Richard Lipton , MD;

10/26/2023

Effects of Solriamfetol on Cognition in Participants with Cognitive Impairment Associated with Excessive Daytime Sleepiness in Obstructive Sleep Apnea: SHARP Study Results

The SHARP trial evaluated solriamfetol's effect on cognitive function in patients with obstructive sleep apnea (OSA) and excessive daytime sleepiness (EDS)-related cognitive impairment. T...

Charles Shinaver , PhD;

10/26/2023

Efficacy and Engagement With a Digital Therapeutic in Patients With Experiential Negative Symptoms of Schizophrenia

Currently, there are no effective pharmacotherapies approved for experiential negative symptoms (ENS) of schizophrenia. Digital therapeutics (DTx) may represent a feasible option given ub...

Brendan Hare , PhD;

10/26/2023